Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about U.S.FDA expanded indication for Synjardy
The U.S. Food and Drug Administration has approved an expanded indication for Synjardy^® (empagliflozin and metformin hydrochloride) tablets to include treatment-naïve adults with type 2 diabetes (T2D). SYNJARDY, from Boehringer Ingelheim and Eli Lilly and Company, is indicated as an adjunct to diet and exercise to improve glycemic control in adults with T2D when treatment with both empagliflozin and metformin is appropriate.
- Read more about Cerulean’s CRLX101 Receives FDA Fast Track Designation
Cerulean Pharma, a clinical-stage company developing nanoparticle-drug conjugates (NDCs), announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for Cerulean's lead nanoparticle-drug conjugate, CRLX101, in combination with paclitaxel, for the treatment of platinum-resistant ovarian carcinoma, fallopian tube or primary peritoneal cancer.
- Read more about U.S. FDA approve Allergan & Adamas New Expanded label for NAMZARIC
Allergan plc and Adamas Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved a new, expanded label for NAMZARIC^® (memantine and donepezil hydrochlorides) extended-release, a once-daily, fixed-dose combination of memantine hydrochloride (a NMDA receptor antagonist) and donepezil hydrochloride (an acetylcholinesterase inhibitor, AChEI).
- Read more about Ajanta Pharma launch Omeprazole and Sodium Bicarbonate Capsules in US Market
Ajanta Pharma Limited received final approval from US FDA and launched Omeprazole and Sodium Bicarbonate Capsules in the US market, through its wholly owned subsidiary Ajanta Pharma USA Inc.
- Read more about Janssen’s Chewable Mebendazole Tablets NDA received Priority Review Designation by U.S. FDA
U.S. Food and Drug Administration (FDA) has granted Priority Review designation for the New Drug Application (NDA) for a 500mg chewable tablet formulation of mebendazole from Janssen Pharmaceuticals.
- Read more about Breastfeeding Mothers can avoid transmission with HIV therapy
For HIV-infected mothers whose immune system is in good health, taking a three-drug antiretroviral regimen during breastfeeding essentially eliminates HIV transmission by breast milk to their infants, according to results from a large clinical trial conducted in sub-Saharan Africa and India
- Read more about New and fast algorithm to know protein-protein interaction
Biologists and mathematicians from MIPT, Stony Brook University and other scientific research centres have taught a computer to predict the structure of protein complexes in a cell 10 times faster than before. The study has been published in Proceedings of the National Academy of Sciences of the USA.

[adsense:336x280:8701650588]
- Read more about FDA Grants Auris Medical Fast Track Designation for Keyzilen
US Food and Drug Administration (FDA) has granted fast track designation for Auris Medical's Keyzilen^TM (AM-101) in acute peripheral (inner ear) tinnitus following cochlear injury or otitis media in adults.
- Read more about FDA approved generic of Nilandron
ANI Pharmaceuticals has received approval from the U.S. Food and Drug Administration (FDA) of the Abbreviated New Drug Application (ANDA) for nilutamide tablets which is first generic competitor to Nilandron®. Trailing twelve- month sales of Nilandron® were $23 million according to IMS Health.
- Read more about SPARC Licenses ELEPSIA XR to Sun Pharma
Sun Pharma Advanced Research Company Ltd. And Sun Pharmaceutical Industries Ltd. and includes its subsidiaries or associate companies) announced a licensing arrangement for SPARC’s ELEPSIA XRTM (Levetiracetam Extended Release tablets).